2900 Predictors of survival in glioblastoma patients treated with fotemustine at first relapse after Stupp regimen: Analysis of GLIOSTRY (GLIOblastoma regiSTRY) of the AINO (Italian Association of Neuro-Oncology)
Giuseppe Lombardi(University of Pisa), Roberta Rudà, Antonio Silvani, Andrea Pietro Sponghini(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Ivan Lolli(Gastroenterology Hospital "Saverio de Bellis"), Matteo Santoni(University of Macerata), Marina Faedi(Inserm), Veronica Villani(Istituti di Ricovero e Cura a Carattere Scientifico), Simona Vallarelli, Vittorina Zagonel(Istituto Oncologico Veneto), Maurizio Salvati, Maria Grazia Fabrini, F. Imbesi, Manuela Caroli, Riccardo Soffietti(Azienda Ospedaliero Universitaria San Giovanni Battista), Domenico Bilancia(Azienda Ospedaliera Ospedale San Carlo Borromeo), Alfredo Marinelli(University of Naples Federico II), Silvia Scoccianti, M. Balducci(Agostino Gemelli University Polyclinic), Mauro Arcicasa
Cited by 0
Related Papers
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
Adjuvant Whole-Brain Radiotherapy Versus Observation After Radiosurgery or Surgical Resection of One to Three Cerebral Metastases: Results of the EORTC 22952-26001 Study
|Journal of Clinical Oncology|2010|2k
EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood
|Nature Reviews Clinical Oncology|2020|1.9k
Response assessment criteria for brain metastases: proposal from the RANO group
|The Lancet Oncology|2015|1.1k
Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer
|New England Journal of Medicine|2014|1.1k